Group 1 - The company Maiwei Bio announced on September 18 that it repurchased approximately 140,000 shares through centralized bidding, accounting for about 0.03% of its total share capital of approximately 400 million shares [1] - The highest price for the repurchased shares was 58.02 RMB per share, while the lowest price was 52.79 RMB per share [1] - The total amount of funds used for the repurchase was approximately 7.36 million RMB [1]

格隆汇9月18日丨迈威生物(688062.SH)公布，2025年9月18日，公司通过集中竞价交易方式首次回购公 司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/ 股，支付的资金总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。 ...

证券代码：688062 证券简称：迈威生物 公告编号：2025-054 公司于 2025 年 9 月 17 日召开第二届董事会第二十二次会议，审议通过了《关 于调整回购股份价格上限的议案》，同意将回购股份价格上限由人民币 48.00 元/股 （含）调整为人民币 66.46 元/股（含）。具体内容详见公司于 2025 年 9 月 18 日在 上海证券交易所网站（www.sse.com.cn）上披露的《关于调整回购股份价格上限的 公告》（公告编号：2025-053）。除上述调整外，回购股份方案的其他内容不变。 二、 首次实施回购股份的情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司首次实施回购股份情况公告如下： 迈威（上海）生物科技股份有限公司 关于以集中竞价交易方式首次回购股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/27 | | --- | --- | | 回购方案实施期限 | 年 月 日~ ...

智通财经APP讯，迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回 购公司股份135,938股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为 52.79元/股，支付的资金总额为人民币736.14万元。 ...

迈威生物(688062.SH)发布公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938 股，占公司总股本的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资 金总额为人民币736.14万元。 ...

迈威生物公告，2025年9月18日，公司通过集中竞价交易方式首次回购公司股份135,938股，占公司总股 本399,600,000股的比例约为0.03%，回购成交的最高价为58.02元/股，最低价为52.79元/股，支付的资金 总额为人民币7,361,397.22元（不含印花税、交易佣金等交易费用）。本次回购股份符合相关法律法规 及公司回购股份方案的规定。 ...

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index closing at 3852.23 points, down 0.62% and below the five-day moving average, while the total trading volume reached 23,670.80 billion yuan [1]. Group 1: Market Performance - As of the latest data, 328 A-shares have surpassed the five-day moving average, indicating a mixed performance in the market [1]. - The total trading volume in the A-share market today is reported at 23,670.80 billion yuan [1]. Group 2: Individual Stock Performance - The stocks with the highest deviation from the five-day moving average include: - 德众汽车 (Dazhong Automobile) with a deviation rate of 22.13%, experiencing a daily increase of 30.00% and a turnover rate of 30.84% [2]. - 福事特 (Fushite) with a deviation rate of 13.88%, increasing by 18.86% today with a turnover rate of 22.61% [2]. - 亿华通 (Yihua Tong) showing a deviation rate of 10.10%, up by 13.75% with a turnover rate of 13.36% [2]. - Other notable stocks with significant performance include: - 沃尔德 (World) with a deviation rate of 8.54% and a daily increase of 14.82% [2]. - 兴业科技 (Xingye Technology) with a deviation rate of 8.27% and a daily increase of 10.01% [2].

Market Overview - The Shanghai Composite Index is at 3894.62 points, above the five-day moving average, with an increase of 0.47% [1] - The total trading volume of A-shares is 12,225.01 billion yuan [1] Stocks Performance - A total of 591 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dezhong Automobile: 22.13% deviation, with a price increase of 30.00% [1] - Xingye Technology: 8.27% deviation, with a price increase of 10.01% [1] - Hanzhong Precision: 8.11% deviation, with a price increase of 9.99% [1] - Other stocks with smaller deviation rates include Tongrentang, China Satellite, and Hengyu Environmental Protection, which have just crossed the five-day moving average [1] Detailed Stock Data - The report includes a detailed table of stocks that broke the five-day moving average on September 18, with their respective trading performance, turnover rates, and deviation rates [1][2]

消息面上，迈威生物发布公告称，公司与Kalexo Bio, Inc.公司（以下简称"Kalexo"）就2MW7141项目相 关签署《独家许可协议》及《优先股股权购买协议》。根据许可协议和股权购买协议，迈威生物许可 Kalexo就2MW7141项目相关在全球范围的独家开发、生产和商业化以及其他方式开发许可产品的权 利。迈威生物将从Kalexo获得最高可达10亿美元的预付款和里程碑付款，以及低个位数的特许权使用 费，其中包括一次性、不可返还的首付款及近端付款1200万美元现金，作为对价的一部分，迈威生物将 在符合约定条件下另外获得Kalexo总计双位数的A轮优先股。 北京商报讯（记者 丁宁）9月18日，迈威生物（688062）以涨停开盘，开盘报58.03元/股，涨幅为 20%。 ...

迈威生物20cm一字涨停，公司与Kalexo签署独家许可协议，最高可获10亿美元预付款和里程碑付款。 ...